Evidence map›Paper›PMID 41174767›Full record

ArticleGenome medicine2025

Spatial-reprogramming derived GPNMB

Yinfei Du, Xinmiao Long, Xuetong Li, Fan Guan, Wei Gao, Kun Deng, Shiyi Wang, Xiang Lin, Meng Huang, Xiaoling She and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genome medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yinfei Du *The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Central South University, Changsha, Hunan, 410013, China.
Xinmiao Long *The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Central South University, Changsha, Hunan, 410013, China.
Xuetong LiThe Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Central South University, Changsha, Hunan, 410013, China.
Fan GuanThe Key Laboratory of Carcinogenesis of the Chinese Ministry of Health, The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, Hunan, 410078, China.
Wei GaoThe Key Laboratory of Carcinogenesis of the Chinese Ministry of Health, The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, Hunan, 410078, China.
Kun DengThe Key Laboratory of Carcinogenesis of the Chinese Ministry of Health, The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, Hunan, 410078, China.
Shiyi WangThe Key Laboratory of Carcinogenesis of the Chinese Ministry of Health, The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, Hunan, 410078, China.
Xiang LinThe Key Laboratory of Carcinogenesis of the Chinese Ministry of Health, The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, Hunan, 410078, China.
Meng HuangDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Xiaoling SheDepartment of Pathology in Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
Shuai ChenThe Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Central South University, Changsha, Hunan, 410013, China.
Minghua WuThe Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Central South University, Changsha, Hunan, 410013, China. wuminghua554@aliyun.com.

Funding

Changsha Municipal Natural Science Foundation kq2403124Fundamental Research Funds for Central Universities of the Central South University 1053320222607,1053320230888Key Research and Development Plan of Hunan Province 2024DK2006National Natural Science Foundation of China 82073096National Students' platform for innovation and entrepreneurship training program S202510533107Provincial Natural Science Foundation of Hunan 2025JJ30039, 2025JJ60852Scientific Research Program of FuRong Laboratory No. 2023SK2085
6 · The paper itself

Abstract

backgroundNeoadjuvant therapy plays an important role in the treatment of glioblastoma (GBM), but a considerable proportion of patients remain unresponsive to the combination of immune checkpoint blockade (ICB) and antiangiogenic therapy. Understanding the mechanisms underlying resistance to this treatment and developing novel therapeutic strategies are crucial.

methodsWe integrate extensive single-cell and spatial transcriptomic data to dissect the cellular composition and spatial organization of the GBM tumor microenvironment and validate our findings through experiments such as multiplex immunohistochemistry and atomic force microscopy. We applied 101 machine learning algorithms to evaluate the prognostic and immunological value of COL6A3

resultsWe constructed a stromal cell atlas in GBM and identified a distinct subset of COL6A3

conclusionsOur findings highlight the critical role of COL6A3

Indexed as

Brain NeoplasmsCancer-Associated FibroblastsCellular ReprogrammingCollagen Type VIFibroblastsGlioblastomaMacrophagesMembrane GlycoproteinsFibrosisHumansTumor MicroenvironmentCollagen Type VIGPNMB protein, humanMembrane GlycoproteinsAnti-angiogenic agentsCancer-associated fibroblastsImmune checkpoint blockadeSingle-cell RNA sequencingTumor-associated fibroblastsTumor-associated macrophages

Identifiers

PMID41174767
PMCPMC12577258

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.